8-K: MAIA Biotechnology Secures $1.51M in Private Placement

MAIA Biotechnology, a clinical-stage biopharmaceutical company, announced a private placement raising approximately $1.51 million to fund its Phase II trial THIO-101 and for working capital.

Summary

• MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement on December 16, 2025, for a private placement.
• The company will issue and sell an aggregate of 1,233,488 shares of common stock at $1.224 per share.
• Warrants to purchase an equal number of common stock shares (1,233,488) are also being issued, with an exercise price of $1.36 per share.
• The warrants become exercisable six months after issuance and have a three-year term.
• The private placement is expected to generate approximately $1.51 million in gross proceeds.
• Net proceeds will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital.
• Certain company directors participated in the private placement, subscribing for 179,737 shares and 179,737 warrants for an aggregate of approximately $219,998.
• The securities issued are restricted and have not been registered under the Securities Act of 1933, as amended, and do not include registration rights.

Sentiment

Score: 7

Explanation: The filing indicates a positive step for MAIA Biotechnology by securing funding for its clinical trial and operations. While there is dilution and the securities are restricted, the capital infusion is crucial for a clinical-stage company and shows continued progress in its development pipeline. Director participation adds a layer of confidence.

Positives

• Successfully raised approximately $1.51 million in gross proceeds, providing capital for operations and clinical development.
• Funding is specifically allocated to advance Step 1 of Part C of the Phase II trial THIO-101, indicating progress in its lead immunotherapy program.
• Participation of company directors in the private placement demonstrates alignment of interests between management and stockholders.

Negatives

• The shares and warrants issued in the private placement are restricted securities and do not include registration rights, which may limit liquidity for investors.
• The issuance of new shares and warrants will result in dilution for existing shareholders.

Risks

• The securities issued are restricted and have not been registered under the Securities Act, meaning they cannot be offered or sold except pursuant to an effective registration statement or an available exemption from registration.
• The absence of registration rights for the shares and warrants sold in the private placement limits the holders' ability to resell these securities publicly.
• Forward-looking statements regarding clinical trials, regulatory approvals, and commercialization are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.
• Hedging activities by purchasers, including short sales or derivative transactions, could negatively impact the market price of the company's publicly-traded securities.

Future Outlook

The company intends to use the net proceeds from the private placement to fund the starting cost for Step 1 of Part C of the Phase II trial THIO-101 and for working capital. Future activities include the initiation, timing, cost, progress, and results of preclinical and clinical studies, advancing product candidates, regulatory filings and approvals, and commercialization efforts.

Industry Context

This private placement provides crucial funding for MAIA Biotechnology, a clinical-stage biopharmaceutical company, to advance its lead immunotherapy program, THIO-101, for cancer treatment. For companies in this stage, securing capital is vital for progressing through expensive clinical trials. The focus on telomere targeting agents for NSCLC patients positions MAIA in a competitive and innovative segment of immuno-oncology, where novel mechanisms of action are sought to improve patient outcomes.

Corporate Governance

Related Party Transactions

• Company director Louie Ngar Yee subscribed to purchase 81,699 Director Shares and 81,699 Director Warrants for approximately $100,000.
• Company director Stan Smith subscribed to purchase 57,189 Director Shares and 57,189 Director Warrants for approximately $70,000.
• Company director Steven Chaouki subscribed to purchase 40,849 Director Shares and 40,849 Director Warrants for approximately $50,000.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and warrants, but the capital raise funds critical clinical trials, potentially increasing long-term value if successful. Lack of registration rights for new securities may affect liquidity for new investors.
• Employees: Continued funding for operations and clinical trials supports job security and the company's mission.
• Customers (future patients): Funding for the THIO-101 trial could lead to the development of new cancer therapies.
• Creditors: The capital raise strengthens the company's financial position, potentially improving its ability to meet obligations.

Next Steps

• Closing of the private placement, expected on or about December 18, 2025.
• Use of net proceeds to fund Step 1 of Part C of the Phase II trial THIO-101.
• Use of net proceeds for general working capital.
• Company will apply to list or quote all Investor Shares and Investor Warrant Shares on its Trading Market.

Key Dates

Recommendation

The private placement provides essential funding for MAIA Biotechnology's clinical development, specifically for its Phase II trial THIO-101, which is a positive step for a clinical-stage biopharmaceutical company. Director participation also signals internal confidence. However, the significant dilution from the issuance of new shares and warrants, coupled with the lack of registration rights for these securities, presents a near-term headwind. The company remains in a high-risk, high-reward stage, dependent on clinical trial success. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive funding news while recognizing the inherent risks and dilution.

Keywords

MAIA Biotechnology, Private Placement, Common Stock, Warrants, Capital Raise, Clinical Trial Funding, THIO-101, Immunotherapy, Cancer Treatment, Restricted Securities, SEC Filing, Biopharmaceutical